Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

4/30/2021 API Import to Russia in 2020

The total volume of API import to Russia reached an all-time high in 2020 in both monetary and physical terms, amounting to 14.4 thousand tons of APIs, worth 167.1 billion rubles (customs clearance and VAT included). The growth rates are +26.6% in monetary and +13% in physical terms.

4/29/2021 Pharmaceutical Drug Production in Russia (March 2021)

Russian manufacturers produced 149.6 billion rubles worth of pharmaceutical drugs between January and March 2021 (manufacturer’s prices, VAT included), up 47% from the same period last year in monetary terms (rubles). While it is early to make predictions, it has been the highest growth rate in five years. The growth rate in physical terms (units) was +7%, with the production volume of 1.07 billion units. The growth rate was even lower, if calculated in MDUs (minimum dosage units), reaching 4.2%, with the production volume of 19.4 billion MDUs.

4/28/2021 Import of Veterinary Drugs and Feed Supplements to Russia (December 2020)

Russia imported 34.5 billion rubles worth of veterinary drugs in 2020 (customs clearance and VAT included), down 8.4% in monetary terms (rubles) from 2019. The seemingly negative growth rate was due to the high-base effect, since back in 2019, the market players had stocked up their warehouses to get ready for the upcoming regulatory changes. As for feed supplements, the import volume amounted to 40.2 billion rubles, with the growth rate of +10.5%.

4/21/2021 RNC Pharma Study: Features of the Commodity Circulation in the Commercial Pharmaceutical Market in Russia in 2020

At the first stage of the movement, more than 82% of all goods are shipped from distributors to the final destination, which is pharmacies, healthcare facilities and others. Pharmacies are, without a doubt, the main channel for the commercial market, accounting for more than 75% of the total volume of the first stage shipments. Another 5% are shipped to the warehouses of pharmacy chains, and then the goods are redistributed to specific points of sale by the pharmacy chain’s own logistics services.

4/8/2021 Pharmaceutical Drug Production in Russia (February 2021)

Between January and February 2021, Russian manufacturers produced RUB 101.4 bln worth of pharmaceutical drugs (manufacturer’s prices, VAT included), which is in monetary terms (rubles) 61% higher than in 2020. The growth rate in physical terms (units) is a bit lower, +16%, with the production volume of 700 mln units. If calculated in minimum dosage units (MDU), the growth rate is only +2.4% and the production volume is 11.9 bln MDUs.

All news [251]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.